Bellicum Pharmaceuticals (NASDAQ:BLCM) Coverage Initiated by Analysts at initiated coverage on shares of Bellicum Pharmaceuticals (NASDAQ:BLCMGet Rating) in a research report issued on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

BLCM has been the topic of a number of other research reports. TheStreet downgraded Bellicum Pharmaceuticals from a “c-” rating to a “d-” rating in a report on Friday, April 8th. LADENBURG THALM/SH SH initiated coverage on Bellicum Pharmaceuticals in a research report on Wednesday, February 16th. They issued a “buy” rating and a $5.00 price objective for the company. Finally, Zacks Investment Research cut Bellicum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday.

BLCM stock opened at $1.52 on Thursday. Bellicum Pharmaceuticals has a one year low of $1.36 and a one year high of $4.04. The firm has a market capitalization of $13.00 million, a PE ratio of -1.31 and a beta of 1.46. The firm has a 50-day moving average of $1.82 and a two-hundred day moving average of $1.75.

Bellicum Pharmaceuticals (NASDAQ:BLCMGet Rating) last issued its earnings results on Thursday, March 24th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter. The firm had revenue of $0.50 million during the quarter. As a group, analysts forecast that Bellicum Pharmaceuticals will post -2.23 EPS for the current year.

A hedge fund recently bought a new stake in Bellicum Pharmaceuticals stock. Virtu Financial LLC bought a new stake in Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCMGet Rating) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 21,792 shares of the biopharmaceutical company’s stock, valued at approximately $32,000. Virtu Financial LLC owned approximately 0.26% of Bellicum Pharmaceuticals as of its most recent filing with the SEC. 28.09% of the stock is owned by hedge funds and other institutional investors.

About Bellicum Pharmaceuticals (Get Rating)

Bellicum Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens.

Featured Articles

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with's FREE daily email newsletter.